LUKAS BIOMEDICAL INC.
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
Lukas’s core offering is its patented memory T‑cell immunotherapy (LuLym‑T), using advanced cell‑culture technology to expand and activate a patient’s own immune cells so they can recognize and destroy cancer cells — a treatment with low side effects, hig
Founded Year
2013
Unified Business No.
54318905
Status
Active
Number of Employees
0
Total Paid-in
Capital
418,743,710 (NT$)
Location of Company
Taiwan
, New Taipei City
Exit Status
Emerging Stock Exchange(2020)
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Lukas Biomedical is a Taiwanese biotechnology company focused on immunocellular therapy, committed to developing safe, effective cancer‑treatment solutions that improve patients’ quality of life — built by a team of clinicians and biomedical researchers under a patient‑centered philosophy.
